- Acumen Powered by Robins Kaplan LLP®
- Affirmative Recovery
- American Indian Law and Policy
- Antitrust and Trade Regulation
- Appellate Advocacy and Guidance
- Business Litigation
- Civil Rights and Police Misconduct
- Class Action Litigation
- Commercial/Project Finance and Real Estate
- Corporate Governance and Special Situations
- Corporate Restructuring and Bankruptcy
- Domestic and International Arbitration
- Health Care Litigation
- Insurance and Catastrophic Loss
- Intellectual Property and Technology Litigation
- Mass Tort Attorneys
- Medical Malpractice Attorneys
- Personal Injury Attorneys
- Telecommunications Litigation and Arbitration
- Wealth Planning, Administration, and Fiduciary Disputes
Acumen Powered by Robins Kaplan LLP®
Ediscovery, Applied Science and Economics, and Litigation Support Solutions
March 30, 2023Minnesota Attorney General Keith Ellison and Robins Kaplan Partner Tara Sutton Give Opening Statements in Minnesota’s Lawsuit Against JUUL
March 28, 2023Robins Kaplan LLP Announces 2023 Leadership Council on Legal Diversity (LCLD) Fellow and Pathfinder
March 22, 2023Benchmark Litigation Names Robins Kaplan 2023 Minnesota Law Firm of the Year
April 3, 2023Conference of Tribal Lending Commissioners
April 11-13, 2023Mass Torts Made Perfect Seminar
April 19, 2023FBA Women in MDL, Mass and Class Leadership
March 2023Unintended Consequences of Banning Noncompete Agreements
March 26, 2023What I’ll Be Watching for in the Amgen Oral Arguments
March 2023How an Investor Can Lose More Than Just Their Investment
September 16, 2022Uber Company Systems Compromised by Widespread Cyber Hack
September 15, 2022US Averts Rail Workers Strike With Last-Minute Tentative Deal
September 14, 2022Hotter-Than-Expected August Inflation Prompts Massive Wall Street Selloff
Find additional firm contact information for press inquiries.
Find resources to help navigate legal and business complexities.
Robins Kaplan LLP Investigates Type 2 Diabetes Drugs and Severe Injuries, Including Ketoacidosis
July 7, 2015
In May 2015 the FDA issued Safety Communication, advising that certain Type 2 Diabetes drugs result in a serious condition known as ketoacidosis.1 The FDA reported that it had received reports of 20 cases of ketoacidosis, all of whom required trips to the ER or hospitalizations to treat the ketoacidosis.2 The FDA is continuing to investigate this issue.3
The FDA’s Safety Communication was limited to the class of Type 2 Diabetes drugs known as “sodium-glucose cotransporter-2” or “SGLT2” inhibitors.4 These drugs include:
1) Invokana and Invokamet (canagliflozin and canagliflozin plus metformin);
2) Farxiga and Xigduo XR (dapagliflozin and dapagliflozin plus metformin extended release); and
3) Jardiance and Glyxambi (empagliflozin and empagliflozin plus linagliptin).5
The drugs are approved for use to treat Type 2 diabetes; they have not been approved to treat Type 1 diabetes.6 These drugs cause the kidneys to remove sugar from the body by excreting it through urine, thus lowering blood sugar.
The FDA’s Safety Communication identified ketoacidosis is a possible condition related to the use of SGLT2 inhibitors.7 Ketoacidosis occurs when the body uses fat, rather than glucose, to fuel itself.8 When fat is metabolized, ketones are released into the body.9 Ketones are acids, which in high levels, can be toxic to the body and result in ketoacidosis.10 Symptoms of ketoacidosis are: excessive thirst, frequent urination, nausea and vomiting, abdominal pain, weakness or fatigue, shortness of breath, fruity-scented breath, and confusion.11 Treatment usually consists of intravenous fluid replacement, intravenous electrolyte replacement and/or intravenous insulin therapy.12 Untreated, ketoacidosis can result in death.13
We are also investigating a possible association between the SGLT2 inhibitors and kidney failure, and cardiac events. For a free case evaluation, please call 1.800.553.9910 (toll-free) or contact us online. Our medical advisors are standing by.
If you are interested in having us represent you, you should call us so we can determine whether the matter is one for which we are willing or able to accept professional responsibility. We will not make this determination by e-mail communication. The telephone numbers and addresses for our offices are listed on this page. We reserve the right to decline any representation. We may be required to decline representation if it would create a conflict of interest with our other clients.
By accepting these terms, you are confirming that you have read and understood this important notice.